» Articles » PMID: 28343538

Accelerated Hypofractionated Adjuvant Whole Breast Radiation with Simultaneous Integrated Boost Using Volumetric Modulated Arc Therapy for Early Breast Cancer: A Phase I/II Dosimetric and Clinical Feasibility Study from a Tertiary Cancer Care Centre...

Overview
Specialty Oncology
Date 2017 Mar 28
PMID 28343538
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Hypofractionation has become standard of care after Breast Conserving Therapy (BCT) in many European and few others western countries. Though still debatable, tumor cavity boost is routinely practised in our centre. Hypofractionation is not yet the current standard of practice in Asian countries. Employing hypofractionation and simultaneous integrated boost to lumpectomy cavity with conformal technique is not the current practice in this region. Hence the study was performed to see whether accelerated hypofractionation and simultaneous boost can be combined using volumetric modulated arc therapy (VMAT) in treating early breast cancer (EBC) patients.

Patients And Methods: Female patients with EBC treated by whole breast radiation and boost were treated simultaneously to a dose of 40.5Gy and 48Gy in fifteen fractions over three weeks to entire breast and tumor cavity respectively with VMAT. Dosimetry including target coverage, OAR (organ at risk) sparing and acute radiation toxicity were evaluated.

Results: Ten consecutive patients were treated. Planning target volume (PTV) coverage and OAR sparing were mostly satisfactory. Mean volume of PTV and PTV were 786.18cm and 228.9cm respectively. Mean D to PTV and PTV were 41.9Gy and 49.1Gy respectively. Dmax to PTV and PTV were 127.56% and 110.67% respectively. Ipsilateral lung mean dose and V20 were 13.92Gy and 21.53% respectively. V40 and V25 of heart were 0.17% and 2.25% respectively. All patients are disease free after a median follow up of two years. Most acute toxicities were Grade1. Only two patients out of ten developed Grade 2 skin reaction during radiation. Early cosmesis using Harvard cosmesis scale is good to excellent.

Conclusions: Accelerated hypofractionated RT using SIB-VMAT is a clinically feasible technique with acceptable initial result. Initial results are encouraging.

Mini Abstract: Simultaneous integrated boost with accelerated hypofractionated whole breast radiotherapy using Volumetric Modulated Arc Therapy is a novel approach. Patient selection and technical considerations are of paramount importance. The present study describes successful implementation of this approach.

Citing Articles

Single-Institution Prospective Evaluation of Moderately Hypofractionated Whole-Breast Radiation Therapy With Simultaneous Integrated Boost With or Without Lymphatic Drainage Irradiation After Breast-Conserving Surgery.

Unterkirhere O, Stenger-Weisser A, Kaever A, Hoeng L, Jeller D, Logaritsch P Adv Radiat Oncol. 2023; 8(6):101270.

PMID: 38047219 PMC: 10692289. DOI: 10.1016/j.adro.2023.101270.


Hypofractionated whole breast irradiation with simultaneous integrated boost in breast cancer using helical tomotherapy with or without regional nodal irradiation: A report of acute toxicities.

Chitapanarux I, Nobnop W, Onchan W, Klunklin P, Nanna T, Sitathanee C Front Oncol. 2023; 13:1122093.

PMID: 37007149 PMC: 10064045. DOI: 10.3389/fonc.2023.1122093.


Adjuvant hypofractionated radiotherapy with simultaneous integrated boost after breast-conserving surgery: A systematic literature review.

Schmitt M, Menoux I, Chambrelant I, Hild C, Petit T, Mathelin C Transl Oncol. 2022; 22:101456.

PMID: 35609442 PMC: 9125620. DOI: 10.1016/j.tranon.2022.101456.


Chair Heterogeneity Index: Describing the dose heterogeneity inside the tumor volume where there is a boost volume.

Mu J, Xi D, Ding Y, Gu W, Li Q Sci Rep. 2018; 8(1):9763.

PMID: 29950564 PMC: 6021440. DOI: 10.1038/s41598-018-28110-9.


Advantages of a technique using two 50 degree arcs in simultaneous integrated boost radiotherapy for left-sidebreast cancer.

Xi D, Ding Y, Hu R, Gu W, Mu J, Li Q Sci Rep. 2017; 7(1):14748.

PMID: 29116237 PMC: 5677093. DOI: 10.1038/s41598-017-15307-7.